From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade?

European Heart Journal

Volumn 33, Issue 1, 2012, Pages 16-25

  Serruys, Patrick W ^a   Garcia Garcia, Hector M ^a   Onuma, Yoshinobu ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; METAL COMPLEX; TISSUE SCAFFOLD;

CORONARY STENT; DEVICES; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HISTORY OF MEDICINE; HUMAN; NOTE; PRIORITY JOURNAL; TREATMENT INDICATION;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DRUG IMPLANTS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL REVASCULARIZATION; TISSUE SCAFFOLDS; VENTRICULAR REMODELING;

EID: 84855505808     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr384     Document Type: Note

References (68)

1. European perspectives. Circulation 2010;121:f1-f6.
2. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.
3. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Circulation 1997;96:468-474. (Pubitemid 27329422)
4. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706. (Pubitemid 17036474)
5. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
6. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS,Walker C, Stagg J. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991;83:148-161.
7. Serruys PW, Keane D. The bailout stent. Is a friend in need always a friend indeed? Circulation 1993;88(5 Pt 1):2455-2457. (Pubitemid 23326126)
8. Schwartz RS, Topol EJ, Serruys PW, Sangiorgi G, Holmes DR Jr. Artery size, neointima, and remodeling: time for some standards. J Am Coll Cardiol 1998;32:2087-2094. (Pubitemid 29010481)
9. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010;56(Suppl. 10):S1-S42.
10. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-a. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495. (Pubitemid 24256751)
11. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501. (Pubitemid 24256752)
12. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy JJ, Vogt P, Kappenberger L, Sigwart U. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13-17.
13. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195. (Pubitemid 32095401)
14. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22:2125-2130. (Pubitemid 33091454)
15. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780. (Pubitemid 34586912)
16. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-2441. (Pubitemid 46717966)
17. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. (Pubitemid 43929240)
18. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-399.
19. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18:70-74.
20. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP, Tcheng JE, Greenfield JC Jr. Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 1988;62(10 Pt 2):3F-24F.
21. Babalik E, Gulbaran M, Gurmen T, Ozturk S. Fracture of popliteal artery stents. Circ J 2003;67:643-645. (Pubitemid 36834397)
22. Okamura T, Serruys PW, Regar E. Three-dimensional visualization of intracoronary thrombus during stent implantation using the second generation, Fourier domain optical coherence tomography. Eur Heart J 2010;31:625.
23. Eggebrecht H, Rodermann J, Hunold P, Schmermund A, Bose D, Haude M, Erbel R. Images in cardiovascular medicine. Novel magnetic resonancecompatible coronary stent: the absorbable magnesium-alloy stent. Circulation 2005;112:e303-e304.
24. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
25. van der Giessen WJ, Slager CJ, van Beusekom HM, van Ingen Schenau DS, Huijts RA, Schuurbiers JC, de Klein WJ, Serruys PW, Verdouw PD. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol 1992;5:175-185.
26. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404. (Pubitemid 30490677)
27. Onuma Y, Garg S, Okamura T, Ligthart J, van Geuns RJ, de Feijter PJ, Serruys PW, Tamai H. Ten-year follow-up of the Igaki-Tamai stent a posthumous tribute to the scientific work of Dr. Hideo Tamai. EuroIntervention 2010;5(Suppl. F):F109-F111.
28. Onuma Y, Serruys P, Perkins L, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography (OCT) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human OCT images in the ABSORB trial. Circulation 2010 (in press).
29. Tsuji T, Tamai H, Igaki K, Hsu Y-S, Kosuga K, Hata T, OKada M, Nakamura T, Fujita S. Four-year follow-up of the biodegradable stent (IGAKI-TAMAI Stent). Circ J 2004;68(Suppl. 1):135.
30. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
31. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-2312.
32. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-1875. (Pubitemid 46829357)
33. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011;123:779-797.
34. Glagov S, Bassiouny HS, Sakaguchi Y, Goudet CA, Vito RP. Mechanical determinants of plaque modeling, remodeling and disruption. Atherosclerosis 1997; 131(Suppl.):S13-S14. (Pubitemid 27306752)
35. Kolodgie FD, Burke AP, Nakazawa G, Virmani R. Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? Arterioscler Thromb Vasc Biol 2007;27:986-989. (Pubitemid 46641964)
36. Ramcharitar S, Garcia-Garcia HM, Nakazawa G, Kukreja N, Ligthart J, Virmani R, Serruys PW. Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents. EuroIntervention 2007;3:290-291.
37. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-1322.
38. Radu M, Jorgensen E, Kelbaek H, Helqvist S, Skovgaard L, Saunamaki K. Strut apposition after coronary stent implantation visualised with optical coherence tomography. EuroIntervention 2010;6:86-93.
39. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, Prati F, Serruys PW. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J 2010;31:1470-1476.
40. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007;69:128-131. (Pubitemid 46052603)
41. Sarno G, Onuma Y, Garcia Garcia HM, Garg S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Ormiston JA, Serruys PW. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 2010;75:914-918.
42. Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007;3:241-244. (Pubitemid 46752686)
43. Verheye S, MartinetW, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007;49:706-715. (Pubitemid 46205042)
44. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182.
45. Wentzel JJ, Whelan DM, van der Giessen WJ, van Beusekom HM, Andhyiswara I, Serruys PW, Slager CJ, Krams R. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-1295.
46. Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000;35:1580-1589. (Pubitemid 30307504)
47. Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, van Geuns RJ, Dorange C, Veldhof S, Rapoza R, Whitbourn R, Windecker S, Garcia-Garcia HM, Regar E, Serruys PW. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2011;32:294-304.
48. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Garg S, Regar E, De Bruyne B, Windecker S, McClean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Dorange C, Veldhof S, Morel MA, de Vries T, Ormiston JA, Serruys PW. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010;3:1190-1198.
49. Thury A, Wentzel JJ, Vinke RV, Gijsen FJ, Schuurbiers JC, Krams R, de Feyter PJ, Serruys PW, Slager CJ. Images in cardiovascular medicine. Focal in-stent restenosis near step-up: roles of low and oscillating shear stress? Circulation 2002;105:e185-e187.
50. Cheng C, Tempel D, Oostlander A, Helderman F, Gijsen F, Wentzel J, van Haperen R, Haitsma DB, Serruys PW, van der Steen AF, de Crom R, Krams R. Rapamycin modulates the eNOS vs. shear stress relationship. Cardiovasc Res 2008;78:123-129. (Pubitemid 351430952)
51. Ciccone WJ 2nd, Motz C, Bentley C, Tasto JP. Bioabsorbable implants in orthopaedics: new developments and clinical applications. J Am Acad Orthop Surg 2001;9:280-288.
52. Resnick N, Yahav H, Shay-Salit A, Shushy M, Schubert S, Zilberman LC, Wofovitz E. Fluid shear stress and the vascular endothelium: for better and for worse. Prog Biophys Mol Biol 2003;81:177-199. (Pubitemid 36551198)
53. Slager CJ, Wentzel JJ, Gijsen FJ, Schuurbiers JC, van der Wal AC, van der Steen AF, Serruys PW. The role of shear stress in the generation of ruptureprone vulnerable plaques. Nat Clin Pract Cardiovasc Med 2005;2:401-407. (Pubitemid 41094126)
54. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, Bruyne Bd, Thuesen L, McClean D, Geuns R-Jv, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-1588.
55. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell, 4th ed. New York: Garland Science, 2002.
56. Cheng C, Noordeloos AM, Jeney V, Soares MP, Moll F, Pasterkamp G, Serruys PW, Duckers HJ. Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation 2009;119:3017-3027.
57. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008;198:39-48. (Pubitemid 351406366)
58. Lehoux S, Tedgui A. Cellular mechanics and gene expression in blood vessels. J Biomech 2003;36:631-643. (Pubitemid 36407615)
59. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122:2288-2300.
60. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-135.
61. Serruys PW, Onuma Y, Ormiston JA, Bruyne Bd, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis six-month clinical and imaging outcomes. Circulation 2010;122:2288-2300.
62. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999;84:166-178. (Pubitemid 29070112)
63. Slepian MJ. Polymeric endoluminal gel paving: therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation. Semin Interv Cardiol 1996;1:103-116.
64. Ramcharitar S, Gonzalo N, van Geuns RJ, Garcia-Garcia HM, Wykrzykowska JJ, Ligthart JM, Regar E, Serruys PW. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol 2009;6:374-378.
65. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation 2005;111:2958-2965. (Pubitemid 40814189)
66. Gijsen FJ, Oortman RM, Wentzel JJ, Schuurbiers JC, Tanabe K, Degertekin M, Ligthart JM, Thury A, de Feyter PJ, Serruys PW, Slager CJ. Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. Am J Cardiol 2003;92:1325-1328. (Pubitemid 37431144)
67. Tanabe K, Gijsen FJ, Degertekin M, Ligthart JM, Oortman RM, Serruys PW, Slager CJ. Images in cardiovascular medicine. True three-dimensional reconstructed images showing lumen enlargement after sirolimus-eluting stent implantation. Circulation 2002;106:e179-e180.
68. Vorpahl M, Finn A, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention 2009;5(Suppl. F):F28-F35.